RT Journal Article
T1 Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles.
A1 Coelho, Maria Caroline Alves
A1 Vasquez, Marina Lipkin
A1 Wildemberg, Luiz Eduardo
A1 Vazquez-Borrego, Mari C
A1 Bitana, Luciana
A1 Camacho, Aline Helen da Silva
A1 Silva, Debora
A1 Ogino, Liana Lumi
A1 Ventura, Nina
A1 Sanchez-Sanchez, Rafael
A1 Chimelli, Leila
A1 Kasuki, Leandro
A1 Luque, Raul M
A1 Gadelha, Monica R
AB Filamin-A (FLNA) plays a crucial role in somatostatin receptor (sst) subtype-2 signaling in somatotropinomas. Our objective was to investigate the in vivo association between FLNA and sst2 expression, sst5 expression, dopamine receptor subtype-2 (D2) expression, somatostatin receptor ligand (SRL) responsiveness and tumor invasiveness in somatotropinomas. Quantitative real-time PCR was used to evaluate the absolute mRNA copy numbers of FLNA/sst2/sst5/D2 in 96 somatotropinomas. FLNA, sst2 and sst5 protein expression levels were also evaluated using immunohistochemistry. The Knosp-Steiner criteria were used to evaluate tumor invasiveness. Median FLNA, sst2, sst5 and D2 copy numbers were 4,244, 731, 156 and 3,989, respectively. Thirty-one of the 35 available tumors (89%) were immune positive for FLNA in the cytoplasm and membrane but not in the nucleus. FLNA and sst5 expression were positively correlated at the mRNA and protein levels (p <0.001 and p=0.033, respectively). FLNA was positively correlated with sst2 mRNA in patients who were responsive to SRL (p=0.014, R=0.659). No association was found between FLNA and tumor invasiveness. Our fndings show that in somatotropinomas FLNA expression positively correlated with in vivo sst5 and D2 expression. Notably, FLNA was only correlated with sst2 in patients who were controlled with SRL. FLNA was not associated with tumor invasiveness.
PB Nature Publishing Group
YR 2018
FD 2018-11-30
LK http://hdl.handle.net/10668/13513
UL http://hdl.handle.net/10668/13513
LA en
NO Tis work was funded by the following grants: Junta de Andalucía (CTS-1406, BIO-0139); Instituto de Salud Carlos III, co-funded by European Union (ERDF/ESF, “Investing in your future”; PI16/00264) and CIBERobn. CIBER is an initiative of Instituto de Salud Carlos III, Ministerio de Sanidad, Servicios Sociales e Igualdad, Spain.
DS RISalud
RD Apr 12, 2025